Subject(s)

Alphapapillomavirus , Cancer Vaccines , Cost of Illness , Health Care Costs , Neoplasms/prevention & control , Neoplasms/virology , Papillomavirus Infections/complications , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Public Health , Cancer Vaccines/administration & dosage , Cancer Vaccines/adverse effects , Cancer Vaccines/immunology , Condylomata Acuminata/prevention & control , Condylomata Acuminata/virology , Esophageal Neoplasms/prevention & control , Esophageal Neoplasms/virology , Female , Genital Neoplasms, Female/prevention & control , Genital Neoplasms, Female/virology , Genital Neoplasms, Male/prevention & control , Genital Neoplasms, Male/virology , Global Health , Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 , Humans , Hungary/epidemiology , Male , Mass Vaccination , Models, Theoretical , Neoplasms/economics , Neoplasms/epidemiology , Neoplasms/immunology , Oropharyngeal Neoplasms/prevention & control , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/economics , Papillomavirus Infections/epidemiology , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/adverse effects , Papillomavirus Vaccines/immunology , Primary Prevention , Respiratory Tract Infections/prevention & control , Respiratory Tract Infections/virology , Secondary Prevention , Vaginal Smears